EGRX - Earnings call transcript Q4 2019 | Eagle Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to today's program. My name is Brie, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals Fourth Quarter and Full Year 2019 Earnings Results Conference Call. All lines will be placed on mute to prevent any background noise. [Operator Instructions]

conference being this X, today, reminder, XXXX. a call recorded is March As my the to Ms. is pleasure It now turn floor to over Lisa Eagle for Wilson, Investor Pharmaceuticals. Relations Please go ahead.

Lisa Wilson

call. Pharmaceuticals Brie. Officer, Eagle for Pete Chief Executive me are quarter to Officer, you, call With Lisa Eagle Meyers. today's Pharmaceuticals’ Thank XXXX Investor Welcome Pharmaceuticals. earnings Financial Eagle This on Relations Scott is Wilson, and fourth Chief Tarriff;

December X XX, a press This release, financial and This XX a the the ended through the and call Company issued release the Investors morning, this section eagleus.com. can XXXX. at accessed results press detailing of of for webcast website, Eagle be

Before regarding may be statements the Reform and the belief, get everyone expectation Private performance I today's future remind Company's forecast, Litigation future express to that made or anticipation defined statements a we projection, any as by Securities and intent would conference started, considered like on call statements forward-looking Act. that

available management projected release statements and the are guarantees with uncertainties, in performance. forward-looking not press based morning's These involve may future today SEC. materially results Such this differ the including Actual those Eagle of and as to on our those forward-looking risks and are of noted statements information from forward-looking Pharmaceuticals statements. filings in

obligation specifically be available will replay update Eagle completion as any these this law. or call. Pharmaceuticals telephone A required to shortly intent disclaims forward-looking by statements, except of after

press in dial-in one-year the find archived today's our information The eagleus.com. on be webcast at You'll for release. will website, available

have and to Since X, recorded discussed. to this benefit archived was those then, made held webcast, the related XXXX. listening the topics or March replay announcements of For Eagle may the on call

SEC recent the press So, releases most please filings. Company's and reference

I'll Eagle's turn call And Scott CEO, with to Tarriff. over that, the

Scott Tarriff

you, and good morning, Lisa, Thank everyone.

we momentum late on evolution company. has pleased on XXXX that an continued the into recent that the developments Eagle very all me from of capitalizing pharmaceutical We're support are saying focused the XXXX. with of by into begin Let integrated that

final EHS, Our and filing NorthShore our by with the paying a or host a for injury, other with evidenced Pennsylvania Lilly the approval FDA brain off and including NDA announcements on of efforts settlement traumatic are Alzheimer's important our heat collaboration as partnership with University of for exertional for HealthSystem milestones. stroke several disease company recent PEMFEXY,

proud data Building on the help years, several us five opportunities in three years with we about these ahead. for launches commercial both next projects have readouts potential important advance research, excited year, underway and will the of and this XX the initiatives five we're we to

year in full our share We $XX the have or per $X.XX $XX to or QX, to continued bringing pipeline, and PEMFEXY $X.XX to total R&D plus invested in our non-GAAP a share. legal invest per on related expenses cash advance million for million vasopressin very pipeline we active basis, of

Court stroke I approval profit. revenue Based drug marketed -- current exertional strength be best year BENDEKA, of and for the the by in believe heat current RYANODEX, on-time important an for Appellate affirmation our XXXX is history the following total decision of for in and on assuming to products gross and terms orphan point the our of strength an Eagle's out. could

second in Eagle. and this later generate record what of that can and very we the to to the ODE vasopressin in lunch a year valuable EHS profit, SymBio the payment or that potential for be are we the receive We doesn't could and successful, include start period half. if expect are revenue milestone Again, gross

advance so exclusive meantime, likely which shortly, before year, of agent aspire vasopressin, four ‘XX, launch filed into then in XXXX. In example, ANDA. be launch ALIMTA beginning we too of As MH from the before as will months PEMFEXY to we the pipeline, our RYANODEX EHS end the that will an sales in far off QX be estimate by of XXXX not lead the all nerve anticipated the followed of us to to

Let's hope be year acceleration starting several with significant of the in and through we months, over great the to things making next in revenue gross value, see profit, but going in few pipeline. unfold time how next same and our and years, at terms this the progress

detail the on pipeline in let's care business. Now, of on our turn more side CMS critical to projects the the

RYANODEX. start truly work Let's on the there going with innovative around

transformative have of of we treatment dantrolene we disease which many across states additional are have options for years. hyperthermia, on has believe years. deal malignant uses the the investigation done been five Beyond great past discovery, sodium over multiple that to a This need led urgent

plays Our yield calcium a dantrolene -- in insights role intracellular to continues calcium intra proprietary how homeostasis. into restoring research

In work to Eagle of the in insight their death. calcium in neuron on those fact, diseases work neurological benefit intracellular calcium have based disruptions may regulation. and that disorders in and might and involved lead teams we years levels scientific to that to be changes may treatments academic resolve and with that our pathologies great partners neurodegeneration and identify believe from in-house

Let on me touch each indication turn. in

Xth. working now for exertional heat for been RYANODEX FDA quite with some agreement, on resubmitted time. NDA on based stroke our have on we mutual January And We

the will with is approval expectation be We the product point Xth on date significant for our have this to for PDUFA the We upcoming or July be a before we that a Company. at this that heat opportunity believe market season. on potential this receive date. will And

restore this use cooling. someone treatment, suffering there tremendous up which represent ability know, for in advancement has the RYANODEX approved heat condition. been a As may only product now to you treatment until drug and exertional stroke acute would by in from no currently function this The of life-threatening cognitive treated is to unpredictable

the treatment brain that age We will animal exposure we be are models if second rule to of first-in-class, FDA's indication evaluating a approved. RYANODEX potential before file we this RYANODEX nerve under study year-end. the what to have for the for death the an design NDA with damage of for of our reduces neurons. would secondary which We're working In significantly year this seen on animal commence

are military Defense. initiative supportive product with benefit collaborating the approved, where Research this and to we Army Medical U.S. a of available the U.S. first potential If the is personnel for military This represent civilians. RYANODEX indication Chemical would Institute with

For radiation. Ultimately, will the acute year have is radiation agent this a syndrome, This we ran RYANODEX model indication another a last with pilot will available expect study run we for and FDA. nerve to civilians for military roughly after behind exposure. we and animal which protecting year year meet

Institute. injury pleased with to new we're Bailes, into is who renowned the neurologist, Chairman University treatment especially and Co-Director the Dr. is of thought diagnosis of be NorthShore's, HealthSystem, traumatic leader the the in concussion. NorthShore Dr. career Bailes NorthShore the With of and and brain Department research Neurology world recently a respected TBI the has entered and our dedicated field of working respect indication and to Neurology agreement to with Julian his we

another study of we well. and more human discuss later of and to robust we hypothesis A readout the is animal to plan Specifically, our further design RYANODEX damage the result potential death. have our FDA expected starting explore the will this studies. including of and the in study, date this modulate with may After year as to completion mechanisms forward, of neuron-cell be meet path that some that

the January, announced in worldwide the Alzheimer's a we're on an disease, for mouse with big indication role Our for of on we to effect seeking disease. relates approach Pennsylvania news animal memory Alzheimer's to agreement treatment. and partnership an University will dantrolene in a terms study. for license dysregulation of be other Alzheimer's study of improvement the In a exclusive tests calcium in XX proof-of-concept sodium represents from and a completely Association in with International study about preclinical Readouts of available dantrolene UPenn was that as has unique cognition administration The of at behavioral cognition documented Conference disease, development novel the for results this positive showed Alzheimer's in The we intranasal preclinical July data sodium in the shared disease. XXXX such memory Alzheimer's months. exploring model and

also significant delivery. sodium, work dantrolene generation benefits our of developing studying capable antagonist receptor in In intramuscular addition ryanodine next the we to of see

exciting Our potential address RYANODEX to the a to EA-XXX This for project that. very need. aims with upside do enormous is medical unmet franchise just time

touch vasopressin. me on let briefly Now,

during to As by confident referencing Eagle an to first important very we also trial, We Vasostrict is as is that into if May and for coming we soon extend going we October Vasopressin already. this paragraph We the approval ml. a we're up market It's evidenced know have a are feel to We'll the the our forward lot PEMFEXY. as ANDA product it week believe file which litigations go to X comes XX reminder, our to the settlement court we May trial. as XXth, year. possible early looking when as units us. is tentative and of per on talented or that receive of XXth, victory a

let's our Now, of cancer. advanced our estrogen business. candidate Starting oncology fulvestrant, to breast product with side turn receptor positive for

program. of modifying yet desired. remain initial the important We're final have program our encouraged study pilot yielded this results the fulvestrant We the not and on has and the results program

keep path progress and forward. our you potential on will updated We

We way look continue to we to achieve forward as quite product our best our a objective. learn about the to bit

PEMFEXY of recently for with side PEMFEXY, company effort Lilly in an received milestones, approval Upon difficult invest of million version initial agreement February TYME. option million the developing we for XXXX. the our an and treat and which ready-to-dilute FDA oncology settlement an April time of announced focused certain the uncapped good XXXX the X a January remaining of for pemetrexed final doesn't all of of of upon upfront that We Also is on PEMFEXY as manufacturing, purchase would with exciting well entry will subsequent February. achievement Xst additional equity an in The for marketing XX%. market responsible an news and be a have $XX have in Eagle now business, associated collaboration additional the with paid to that we from XX% TYME $XX of therapeutics Turning require responsible co-promotion initial December million reconstitution. on on to of Eagle in on regulatory, SM-XX with cancers. promotional XXXX, will costs of technologies, development, be $XX to entry

States. United rights all our We in TYME receive the time any may sales net of will at $XXX under million. out buy XX% co-promotion for also agreement also

oncology call I briefly financials, the to important discuss before generics on another touch ‘XX. let are over Before me Pete turn December the asset, expected bendamustine. TREANDA to not

litigation is mentioned outcome pending. years seven I ODE the of of for earlier, for As BENDEKA

expect few in decision next the We months. the

partner $X entitles us approval payment. which product September, anticipates marketing addition, a Japan, SymBio, for In to in milestone our in bendamustine ready-to-dilute its million

the to meaningful ml the before, next of XX to As starting first year magnitude then SymBio and and royalties XXX stated milestones be for the per the ml launching we million $XX bag. year, million could $XX bag

has I involved three XX for a flow, with in As each of hard news very the by upfront, five a work there's reflected better distinct and underway Eagle. next period the for recent market active advantage. launches Eagle, the this never been research potential been said with We and time representing a be product years with projects years, think to

And with to call that, Pete Pete? fourth the turn quarter over our discuss financials. I'll to

Pete Meyers

Scott. you, Thank

the during for revenue of revenue In million and XXXX. increase BENDEKA. million fourth $XXX.X sales. $X.X year $XXX.X included a $XX.X was to RYANODEX primarily $X.X quarter $X sales offset quarter sales, in XXXX $XX.X in total to XXXX, driven by in BENDEKA decrease payment million XXXX, million $XX.X was year-over-year, by decrease in to $XXX,XXX the fourth compared QX million $X.X QX Product partially compared sales, $XX.X million decreased in million million in in BELRAPZO XXXX, a of by an million totaling million, milestone product compared Full

injection ended For to low increased offset and were a cycle driven in in of decreases December lower and discontinuation in of non-alcohol product partially sales of period, sales on RYANODEX BELRAPZO million XXXX, primarily the BENDEKA. $X.X The September, by in due volume increases by year the year docetaxel the sales XXXX. total increased reorder sales XX, product

were sales $X.X quarter recognizes to million product million QX on revenue in the by Eagle Eagle BELRAPZO to BELRAPZO compared shipments wholesalers. $X.X in fourth XXXX.

to was to wholesaler compared market and of data, For XXXX. for the X% million on Based of end-users fourth year. bendamustine market million share IMS full BELRAPZO year, bendamustine in for as sales totaled the X% the shipments $XX.X U.S. quarter Eagle's $XX.X

opportunity compared in with an million, We RYANODEX QX to RYANODEX Fourth expiry is anticipate RYANODEX quarter are for $X.X product were driven expiring. in sales of XXXX. Orders uptick and dantrolene million few by acquiring unless cyclical, primarily product $X.X customers stock their XXXX. expiry

quarter. For in royalty XXXX. royalties compared XXXX. revenue $XX.X was to negatively $XX.X $XX compared $XX.X BENDEKA prior by year the were million, full year, in quarter RYANODEX revenue sales fourth XXXX historical the as million, the to million in million, totaled was to million compared royalty QX pricing $XX.X million QX $XX.X impacted of trends. BENDEKA

royalty translates XXXX, point which rate, was EBITDA. effective incremental in per approximately vial into October However, $XX the increase in X X, on Eagle

million, For $XXX.X in $XXX.X BENDEKA million fourth fourth million the $XXX.X Gross XXXX, compared year, compared quarter to royalties the in quarter royalty to totaled revenue were XX% XXXX. to of $XXX.X in during in margin was XX%, of the XXXX. XXXX, as compared XXXX. million

the to in driven marketing decrease the of partner XXXX expansion in a earns BENDEKA profit increase by Eagle and quarter The in was gross royalty which fourth BENDEKA product margin on revenue. a sale in no

were $X.X largely expenses the prior year-over-year quarter. increase on spending the to attributable $XX.X in in expenses. year R&D payroll front, compared expense the million quarter, million fulvestrant and is to fourth The On

non-recurring compensation other quarter $X.X the non-cash Excluding million. R&D stock-based was fourth and during and expense items,

As $XX.X a Full invested Scott bringing partially of in on we formulation, the pemetrexed. expense to mentioned $X.X and million compared for XXXX, R&D in fulvestrant non-GAAP $XX year legal by of to vasopressin pipeline, million $X.X in million in cost million spending advance million reflecting our in R&D project primarily upfront, $XX.X expense plus expense, to to decreased XXXX, vasopressin market. Company's offset decrease QX,

was and compensation expense non-cash XXXX stock-based and R&D million. Excluding nonrecurring other items, in $XX.X

be on $XX spend in $XX to expect will We XXXX non-GAAP the as $XX basis million million, million in to compared XXXX. R&D

regulatory includes, syndrome; and number and CMC RYANODEX University four exposure NorthShore IND-enabling number vasopressin for and number the the and anticipated the formulation a RYANODEX spend number additional activities; R&D tox of advocacy initiatives; EA-XXX University acute treatment three, for one, work pilot The nerve preparedness XXXX and EA-XXX trial Pennsylvania for studies HealthSystem; two, lastly, development number EA-XXX trials agent radiation and and at PEMFEXY. scale-up five, CMP launch EHS; pre-clinical number six, of

of of totaled with legal compared XXXX as pemetrexed SG&A $XX.X to and of year-over-year expenses quarter the the spend payroll increase. well in External cost fourth quarter associated million million as litigation vasopressin account in most the fourth on XXXX. $XX.X for

compensation SG&A and stock-based nonrecurring items, Excluding was fourth other XXXX million. and quarter expense non-cash $XX.X

as XXXX $XX.X XXXX. on increase. compared $XX.X by spend million to vasopressin $XX.X SG&A well associated most year of year-over-year legal and payroll Full million for million increased expenses litigation in pemetrexed costs in to External the account with as

in Excluding stock-based compensation was and other non-cash and on recurring $XX.X items, SG&A XXXX expense million.

XXXX is If be on largely our external XXXX. increase spend. in launch EHS operating payroll million expect in offset to attributable will to $XX guidance. million and partially to million expense marketing XXXX We higher reset Year-over-year vasopressin lower we spend sales compared will a label legal non-GAAP $XX marketing, SG&A and the by $XX RYANODEX basis expansion costs, is as approved,

above. share $X was $X.XX of for year $XX.X compared in XXXX, net and for share ended XXXX result million per or XX, the basic basic per per or $XX.X diluted million and and $X.XX Net $X.XX per $X.XX of XX, as per basic was or December compared million net prior the per diluted factors to income per diluted discussed million income ended income $X period. of year to or share for Net fourth as a quarter $XX.X the December basic share $X.XX the period the and diluted a $X.XX a income

$X.XX diluted income million to and quarter. non-GAAP diluted per adjusted and $X.XX or per quarter basic XXXX $X.X the net in -- a basic non income fourth of or $X.XX per was prior Adjusted for share per a $XX.X share non-GAAP net of compared million the $X.XX to

or was per $X.XX and per share income net or for in income million non-GAAP non-GAAP share basic Adjusted adjusted of net to and XXXX $X.XX $XX.X $X.XX per million per diluted $X.XX diluted compared XXXX. basic $XX.X

tables please our at full financial net see non-GAAP measures, of press income the release. a For reconciliation to comparable the most the end of

XXXX million in $XX.X shifts XXXX the to $XX.X year Our million $XX XXXX operations quarter $XX.X $XX.X XXXX. was EBITDA quarter. compared in in the EBITDA compared to flow from was Full receivables was cash fourth million excluding million million. for year prior

XX, The $XXX.X cash December of accounts and due XX, in had $XX.X million. million net Therefore, XXXX, $XX million Company cash was receivable, million of equivalents As from $XXX.X Company in and outstanding December debt. had plus of net million the which of receivables $XX Company Teva. XXXX, the cash in as had

Eagle’s XXXX common as XX, our over XXXX, stock. purchased common $XXX.X million From The $X part program. we of we of million $XXX fourth December our August share have XXXX, million through stock repurchase repurchased quarter

open With and that, questions. the ahead operator, please line for go

Operator

first Amsellem David with [Operator from ahead. Our Go question Piper Instructions] Sandler.

Zach Sachar

Zach is my taking for for David. on This Hi. questions. you Thank

is of or the you've target a ones quick vasopressin, that settlement the on development? Just action candidly talk pursuing you. could aggressively, the you couple about the if on second, don't in if broader talked you about you a how Thank in Could question, injectables settlement? And are on XXX whether complete you gotten filing? mind. the any (NYSE:B) past, what of for your with on (X) Endo we provide And gone additional I don't past then, level mind. color date on one litigation the know letter response maybe if and potential you confidence you've settle filing the Could you've quick

Scott Tarriff

you. Thanks for Thank question. the

that we've make approval here will all to think your question previously in expect to possible. what we our timing, time predictions important is I the to have follow-up the that we is, look, So, receive we fully stated that the vasopressin for

a in expect this having market we the up to later the expect then, we rest time relatively to And shortly go we get court, to year. good approval wind if So, here. of

to a when in predict we're the We so we're things. just good or that paragraph terms of believe very to hard that the In in. it comes these settlement, it's position, litigation

court if a decision which goes is already, over. year the of time, we decision get to according before And all in in we'll be you in get May plan, course would normal court a here the

And have of market that. is to to have go in that's expect over. me, excuse to We the approval year before case, -- if our the advance well the opportunity we every

launch the corner. around that so, And is right

in the just we so, that how good may go And of or shape. we'll have. see think discussions we to But, not may with the we're things have rest just

shape in good with We expect to good company we we’ll important important We're are That's We most asset is this the that just element that here. the in The that. shape PEMFEXY. short-term. resolved in monetize takeaway. the very

I we've have what at any projects don't in point have injectables And (B) other about already do to this XXX (X) disclosed. We than other speak XX development.

up launches next years. We the three have several coming in

I think five we mentioned.

And a can about now We're robust excited starting that the have pretty pretty so, we corner. the growth around pipeline. it's just

you. So, to it's time the involved Thank exciting pretty Company. with be

Operator

comes with next Our Stanicky Capital go from question Markets. Randall RBC ahead. Please

Randall Stanicky

and Company. is focus than think potential called $XXX XXXX on we profit Scott, double-digit better million, Great. revenue, just If would Thank you. which that year gross you the be growth. for for to I imply out the the best revenue

So, expectation and how vasopressin question sounds in It is, can through thinking some BENDEKA that as you also well. RYANODEX that, help got us you've royalties? of components about the think you're like

about about setback. through with that forward? the here. Can follow-up of a I the we're I to hear path product And you but, then, release, where it you looks fulvestrant, walk a like and think him bit how the at was there didn't saw talk

Scott Tarriff

Yes. Thank Great, you. Randall.

the the if the on the internal where of our for in up business has of ODE, EHS date. But addition me in appellate sets make But, a expiries. affirmation before And turn the up. to amount season for up cycle look, rather nicely if be the a were EHS not all our forecast doing I'll MH that's that we in expiries Company. the turned wind decision coming time Xth or XXXX up. okay. get obviously over expecting some number well. had to just general also having Pete view, a we And if that July approved three comments is our or by And specifically sales years Let of we very But, XXXX, lot meaningful coming in to approved to there we're next it quarter. first That's driven just in in that, and heat

sales of comments So, think I we my year. that did here could almost QX all as in mentioned I in many we last have as

can So, that revenue. how you our see strengthens

is dramatically BENDEKA relationship doing well, which very of We'll then, end is And hopefully really And then, year, we year. growth pretty should accelerate at could And well a the get SymBio to pretty that a that, a record launch out like the add have milestone would the good happen. year. well. BENDEKA have the you doing into vasopressin potentially of if

Pete, that's to numbers did so, want add And you to where the line? anything those from. else revenue come

Pete Meyers

may. I if Yes,

Let's just and BENDEKA you spend the for minute on royalties Randall the question. a thank

the XXXX were You’ll have noted year that down for BENDEKA full royalties year-over-year. million about $XX

and As compression, talked is on BENDEKA. GTN $XX in calls, a price price about of substantial the the in that we call million component prior compression it,

Our not royalty. is of from volume bit down fourth bump, million quarter offset X you royalty the of $X which incremental do points little the if much, of mathematics quarter was a little a an course around of a bit, an

the diminution of million, Randall. And $XX that year-over-year so, explains

note two appears, at the the on look bendamustine compression appear would based the Randall we it GTN XXXX, the market. into IMS at, go data that that look us be abated trends, telling that one data we in to As we you same has

also an is frankly fourth have And point year three accurate. of in incremental quarter. royalty the when it then rate, remember, five, Let's and another that of full incremental that a of that course, hope quarters

the an label provide cycle. in And will confident of on course, ups a a RYANODEX, given And would of we're approved in be growth the to EHS then, if expansion so, expiry year, you telling BENDEKA year. for we that look EHS royalties have number. even substantial growth absence RYANODEX the

be our break And if so, we best indeed year do way. things could revenue Randall feel our a XXXX few that on

Scott Tarriff

I number be, this place fulvestrant, get setback we're going Randall necessarily that didn't in just on. These there but quite initial that for have results then, to We're we we'll hopefully we we of about And and plans not have And talk about. very us wouldn't news work have where relatively still point. to program at yet. want to encouraged and a additional and Pete. you, soon Thank say thoughts

happens. Let's And, of important an patient obviously just mean, for making hopefully diligently such it company, the amount and very It's for product. I see what the it's the we're working population. right progress. not on but we're

let's get we we'll how we're So continuing But that a on soon. see continues last study that and there breakthrough just to unfold. had. to quite it this have But, we didn't past hopefully here

Randall Stanicky

Great. Thanks guys.

Scott Tarriff

Thanks, Randall.

Operator

Our question Please go Blair. Tim next Lugo with comes from William ahead.

Lachlan Hanbury-Brown

for Lachlan questions. Tim. is the for This Thanks Hey. taking

fulvestrant the on up following Just trial.

sort change terms the accept three in in that And to high second timeline of So, an any there? more determine path sets and EHS, in sort sort there data forward. you your into to or of update of study of is is level the just guess the study that might the And combined provided then the additional confidence I pilot years level overall FDA's of that willingness the beyond the any RYANODEX it that you've there or to is question, have mean past? data of the requiring what on

Scott Tarriff

year and go our then always models gauge in pilot But, have work we've that that the in a timing the recognized may And and more did Let we've are. we healthy that's humans have in a in direction question there me we reformulated first reformulation. we last go back to of realized in where volunteers pilot second repeat the everyone, we spoken terms and do to bit to little to fulvestrant, one. we the of fact that and study first we to

be that So, you, sure sit report then does as there that at just we not human do those in We've we'll may work bit doing a further timelines. prior there's point a we'll while. not significant we to be the have good a pivotal, thoughts. to well for more tell of change I the here pretty timelines. a can't what little to studying There it's today be, been and need likely back. study might some But, and it this very we this quite

the continue every at understand We to and we time requirements it. better look better

let's we give let's more a work know to so, update think, bit I just there's little more a are. than you done. better encouraged, We're do but little than I take to bit we of let's be a time, work, that see And did. where don't still

let's see terms So, you second your we are. to where -- in related And question then, repeat RYANODEX? can

Lachlan Hanbury-Brown

went the Yes. EHS, understand, just combining I years three it from wondering, was of was the the submission And that data the as sort I you to was wondering Hajj. I just from if willingness all. has use -- sets the guess combined I on those is across with your the any FDA, three their data based discussions perception of to years changed at

Scott Tarriff

Yes, I see.

sit had on date. we've expectation have done And process, that work to that PDUFA or be right our during now is, the and the So expecting were knowledge for going before we've will July dialogue that prepare review approval level But approved have to hopefully, on Xth for we're look, before for this the expectation the today, it'll moving our and date. we that to approved forward we're that that this we or be it's in we as work us. this time call launch. turn PDUFA on And

Operator

next from Cantor with comes Fitzgerald. Please go Brandon [Operator Our Instructions] ahead. Folkes question

Brandon Folkes

question. Thanks taking for my Hi.

sales need over years? about can so, priorities the And capital do Do market you there? peak M&A? are to sorry, talk then, should number the your BELRAPZO what forward, royalty? in secondly, you. allocation we Does of you same? feel Thank in XXXX, given what there? do the -- launches that -- think you noted coming the share have step-up BENDEKA can just about a willingness peak going if to strategy Firstly, you need And priorities and the remain talk that about you How strategy the just given

Scott Tarriff

Thanks, Brandon.

that is not strong in been strategy for BELRAPZO earlier, could way we that we bendamustine we're where with in whole step the mentioned very as believe are. staying just working has us. the changed. out look, well. Everything's the Pete which well approaching XXXX, We're together So, obviously pleased We a really, royalty, the coming do up franchise. have have We

in marketplace. don't view changes I any see So, of major our that

that's positive. all very so, And

stability I in we the the market. And, seen let's think, happens move we've see through year. what as

of process And allocation, We our there's We anything three in there that up changed I terms launches have don't in -- projects. years. way. capital thought have these on five either do could along the it's believe coming XX that's

near these about upon the growth think, that just work all spoke things is I we right out term. in if us the us, for

very and have good good forward. do position we opportunity move But, to

lot as do like may have we've to to product and we that but that for and something like say aggressively continue it been trigger exploring has at us to -- look. And anything find infrastructure go add and to we compete makes as we Everything today, not that sense development. and everything today to where two. look. this growth or get And we'd of we on organic the pull to We And should don't and looking profitable through the externally, ahead company that quickly have through And we is things. internally. doing. with we’d obviously more pipeline foremost, support bigger for another a may could can we first think and And look we're we to or

Operator

our take SunTrust. we'll with And next Gregg Gilbert from question

Gregg Gilbert

would practice where maybe kind approval, you how EHS. how Scott. -- it I'm initially. morning, product community of the to you stocked would product. practice And be that awareness be changing ahead curious the characterize wanted could could and Good of us provider their given changing for is their readiness ask be you or Hi. potential think a a I this about

Scott Tarriff

the for Greg. question, And question. Yes. thanks Great

So, interesting in be it's EHS situation. and shaping just to a RYANODEX up general, very

way to stock the give that half or is hospitals X,XXX are there U.S. best in describe of the today. So, take which RYANODEX

We have room, emergency stocking. a the the an of not MH stocking share, That the number or take of in XX% give of in and event situation room. is the in obviously operating hospitals

they're think start product. And patients, are approved, non-stockers going if don't today, an stock think immediately, is to X,XXX about the a So, you the is not let's just hospitals going focus first need to all potentially It's the on stocking Once likely, product. have are that they to to EHS those stock stock. product. need if seeing you're of velocity those we to the we emergency there, that just couple to going have most hospitals

You patient can't while wholesaler exactly have have you it your and a you to delivered call there. sitting

room. so, operating other need be X,XXX have those the hospitals may probably the vials stocking are be hospitals currently there in in to And the that right And then, to four, emergency five back. room, the off stocked then SymBio that they need

emergency because is this to where hospitals and product it's be clearly room have to ready, stock going an are So, situation. an emergency

subjects and I have whatever So, our stroke heat we from growth think emergency we to usage stocking as get two areas, come beginning is the then coming the the at into the going along way room.

Gregg Gilbert

the schools Do getting or in at that like longer trainers or opportunity? that hands ambulances you see athletic product anything or term to a is the of

Scott Tarriff

all. at the happening in short that We midterm don't or Yes. see

think, going drug. be I it's emergency to room

everybody see to get used it's just drug ER-driven use the things how an clearly process. but go, and Let's

Operator

turn back at time. And I'll any there for further speakers the no to remarks. closing it are this questions

Scott Tarriff

Thank you.

of So, I XXXX look, profit, earlier, as growth best an over wrap terms by history just gross the and years revenue period the company. to several in the Eagle’s for really accelerated stated next followed year in be of up, total could

hopefully the includes for the affirming drug nerve and for BENDEKA exclusivity orphan file before approval. this vasopressin, then, EHS launch agents. year is And Now, over,

that entry. still that per had months may $XX value million million injury yourself doesn't $X then launch brain fulvestrant hopefully earlier You of to PEMFEXY four ANDA you 'XX, start still this may traumatic beginning get starting And payment questions from to year, and expect launch this we to milestone with the followed by concussion at include the the then, into we ALIMTA disease. add SymBio in the that the we million from find $XX it anticipated anything was we Alzheimer's today, before and acquire. And year

growth look the upcoming forward reporting over about we so, the progress trajectory are to excited and on weeks months. and And our

the the We and on Thank you. you be for So, Company. greatly the time to support call appreciate with it’s And exciting involved being thank it. today.

Operator

participation. program. appreciate today's does conclude This We your

You disconnect. may now

Eagle Pharmaceuticals (EGRX) 2 Mar 202019 Q4 Earnings call transcript